Used in targeted cancer immunotherapy, this antibody specifically binds to Claudin-6 (CLDN6), a protein overexpressed in various tumors but absent in most healthy tissues. Its high specificity makes it valuable for developing antibody-drug conjugates (ADCs) and chimeric antigen receptor (CAR) T-cell therapies. It enables selective delivery of cytotoxic agents to cancer cells, minimizing damage to normal cells. Additionally, it serves as a reference standard in research for evaluating CLDN6 expression levels and validating new anti-CLDN6 therapeutic candidates. Its role in preclinical studies supports the optimization of dosing, efficacy, and safety profiles in oncology drug development.